(b) The largest treatment gap is potentially within post-ACS care, where patients with SMI and myocardial infarction are less likely to receive aspirin, P2Y12 inhibitors, beta-blockers, statins, ACEIs/ARBs, or MRAs compared with the general population. The majority of patients with SMI have a lower likelihood of undergoing invasive coronary procedures. When treated sufficiently, no differences in post-myocardial infarction mortality are observed between patients with SMI and the general population. Here, P2RY12 is linked to myocardial infarction.